Valvular & structural heart disease
Optimizing patient triage on the waiting list for transcatheter aortic valve replacement: the clinical utility of the cardiac damage staging system
An erratum to this article was published (Eur Heart J Qual Care Clin Outcomes, 23 Jun 2026 ↗)
Authors' conclusion
These findings suggest that TAVR candidates at Généreux stages 3 and 4 should receive higher priority on the waiting list.
Study context
- Population
- Patients referred for transcatheter aortic valve replacement (TAVR)patients who died while on the TAVR waiting list
- Participants
- 98 patients
- Outcome
- All-cause mortality from the time of a patient’s inclusion on the TAVR waiting list or non-proceeding to TAVR
Main finding
As reported in the abstract
- Overall proportion of deceased patients
- 8.4% [95% confidence interval (CI), 6.9-10.1]
- Proportion of deceased patients when excluding deaths occurring after 2019
- 4%
- Deaths by 3 months
- 6.3%
- Deaths by 6 months
- 7.8%
- Deaths that took place within the first 3 months
- 90%
Observational data: associations, not effects.
Further findings
Variables independently associated with mortality on the TAVR waiting list (multivariable analysis)
| sHR (95% CI) | P value | ||
|---|---|---|---|
| Prior myocardial infarction | 1.87 (1.12–3.13) | P = 0.017 | |
| Pulmonary artery systolic pressure > 60 mmHg | 2.37 (1.36–4.12) | P = 0.002 | |
| Généreux stages 3 and 4More than doubling the risk of death | 2.12 (1.33–3.38) | P = 0.002 | |
| 0.20.5125Subdistribution hazard ratio (log scale) |
Patients who had undergone TAVR
- By 3 months
- 61.2%
- At 6 months
- 85.4%
Original publication
Optimizing patient triage on the waiting list for transcatheter aortic valve replacement: the clinical utility of the cardiac damage staging system. Eur Heart J Qual Care Clin Outcomes. Published 3 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →